Dual Excipient Integration in Dry Powder Inhaler Products

Nanopharm explore the effect of dual excipients on DPI products, boosting performance and shaping formulation in the dry powder inhaler landscape.

Alternative Regulatory Pathway for Generic Inhaled Drugs

Uncover the pathways for generic OINDP and the challenges and solutions in the pharmaceutical regulatory landscape for inhalation drug products.

Physiologically-based Pharmacokinetic Models (PBPK) for OINDPs

Aptar Pharma discusses Physiologically based PK models for OINDPs.

Nanopharm’s SmartTrack: Accelerating OINDP Respiratory Drug Delivery

Revolutionize your OINDP respiratory drug delivery with Nanopharm’s SmartTrack. Accelerate development and mitigate risks through expert formulation and integrated solutions. Your pathway to success starts here.

Nanopharm’s Role in OINDP Bioequivalence & Pharmacokinetics

Explore Nanopharm’s groundbreaking methods in OINDP bioequivalence and pharmacokinetics. Learn how in vitro and in vivo studies are revolutionizing drug development and solubility.

Investigating The Propellant Pathways Leading To a Sustainable Future of MDIs

Download the Article Description: The article discusses the transition to low GWP propellants in the respiratory drug delivery sector as current high-GWP variants are phased out. The leading propellant options for the next generation of low GWP MDIs ( metered dose inhalers) are HFA 152a and HFO 1234ze from the hydro-fluoroolefin family. The article highlights […]

Conversations with Dr Julie Suman, on Nasal Drug Delivery: Current trends, technical challenges and opportunities for therapeutic innovation

Aptar Pharma present data on the challenges and opportunities for Nasal drug delivery.

Nasal Drug Development, Trends and Challenges with Nasal Formulations

Nanopharm explores the current trends and technical challenges in nasal drug product development, focusing on formulation.

Nanopharm’s Nasal Spray for SARS-CoV-2 Antibody Treatment

Discover Nanopharm’s innovative nasal spray for SARS-CoV-2. Learn how this prophylactic treatment effectively delivers antibodies for maximum protection.

Unraveling the Pulmonary Fate of Fluticasone and Friends: Meeting the Physiologic and Pharmacokinetic Challenges

Exploring the role of DPI (Dry powder inhaler) in drug development and the inhalation process and pharmacokinetics of fluticasone propionate.